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ABSTRACT
Objective To determine how often health surveys and
qualityoflifeevaluationsreachdifferentconclusionsfrom
those of primary efficacy outcomes and whether
discordant results make a difference in the interpretation
of trial findings.
Design Systematic review.
Data sources PubMed, contact with authors for missing
information, and author survey for unpublished SF-36
data.
Study selection Randomised trials with SF-36 outcomes
(the most extensively validated and used health survey
instrument for appraising quality of life) that were
publishedin2005in22journalswithahighimpactfactor.
Data extraction Analyses on the two composite and eight
subdomain SF-36 scores that corresponded to the time
and mode of analysis of the primary efficacy outcome.
Results Of 1057 screened trials, 52 were identified as
randomised trials with SF-36 results (66 separate
comparisons). Only eight trials reported all 10 SF-36
scores in the published articles. For 21 of the 66
comparisons,SF-36resultswerediscordantforstatistical
significancecomparedwiththeresultsforprimaryefficacy
outcomes. Of 17 statistically significant SF-36 scores
where primary outcomes were not also statistically
significant in the same direction, the magnitude of effect
was small in six, moderate in six, large in three, and not
reported in two. Authors modified the interpretation of
studyfindingsbasedonSF-36resultsinonlytwoofthe21
discordant cases. Among 100 additional randomly
selected trials not reporting any SF-36 information, at
least five had collected SF-36 data but only one had
analysed it.
Conclusions SF-36 measurements sometimes produce
different results from those of the primary efficacy
outcomes but rarely modify the overall interpretation of
randomisedtrials.Qualityoflifeandhealthrelatedsurvey
information should be utilised more systematically in
randomised trials.
INTRODUCTION
Quality of life outcomes and surveys of overall health
status are considered useful to incorporate in rando-
misedtrials.
1-7 Suchdatawould be importanttocollect
and report systematically, regardless of whether the
results agree with the primary outcomes or not. It is
unknown whether it is common for quality of life and
health survey results to reach different conclusions
from those of the primary efficacy outcomes, whether
there is selective reporting of outcomes, or whether
discordant results in these outcomes modify the
conclusions of these trials. We therefore evaluated
recently published trials (2005) in 22 leading journals.
Many generic and disease specific quality of life and
health survey measures exist.
28 Some are difficult to
compareorarepronetomethodologicalshortcomings
andsuboptimalvalidation.
129-11Tomaximisecompar-
ability across trials covering diverse diseases and
interventions we focused on trials using short form-36
(SF-36).Originallydevelopedasamultipurposehealth
survey instrument, SF-36 has been translated in more
than 50 countries as part of the international quality of
life assessment project and has become the most
extensively validated and used generic instrument for
measuring quality of life. It is an instrument that has
extensive applications for population health surveys,
comparisons of relative burden of diseases, and
differentiation of health benefits across groups pro-
duced by diverse interventions.
11-14
METHODS
We considered randomised trials with data on SF-36
published in 2005 in five major general medicine
journals(NewEnglandJournal ofMedicine,JAMA,Lancet,
BMJ, PLoS Medicine) and 17 specialty journals with the
highest impact factor among those that publish
research from clinical trials for 2005 using the 2005
Journal Citation Reports (Circulation, Journal of the
American College of Cardiology, Gastroenterology, Hepatol-
ogy, Journal of the National Cancer Institute, Journal of
Clinical Oncology, Blood, Annals of Internal Medicine,
Diabetes, Diabetes Care, Brain, Annals of Neurology,
AmericanJournalofRespiratoryandCriticalCareMedicine,
Journal of American Society of Nephrology, Arthritis and
Rheumatism, American Journal of Psychiatry, Archives of
General Psychiatry).
We considered randomised trials to be eligible that
reported on any of the two composite (physical,
mental) and eight subdomain SF-36 scores (physical
functioning, role physical, bodily pain, general health,
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health).Whenreferralwasmadetoadditionalseparate
publications reporting primary efficacy or SF-36 out-
comes, these were also retrieved. We also considered
trials using SF-12, a shorter version of SF-36 (for
compositescores).Norestrictionwassetondiseaseand
compared interventions. Whenever information was
not reported on all 10 scores, we asked authors for
missing information.
Wesearchedthe22targetjournalsthroughPubMed
usinglimitsforrandomisedclinicaltrial(typeofstudy)
and 2005 (year of publication). Identified articles were
downloaded in PDF format and screened electroni-
cally using Acrobat Reader “Find” tool for keywords:
quality of life, SF36, SF 36, SF-36, short form 36, short
form-36, SF-12, SF12, mental composite score, physi-
calcompositescore,medicaloutcomestudy,MOS36,
MOS-36,andWare.Articlespassingelectronicscreen-
ing were further evaluated by two independent
investigators (AK and IK). Disagreements were
resolved by consensus. Remaining disagreements
were resolved by DGC-I.
To probe whether SF-36 data may have remained
unpublishedwecommunicated(threeemails,eachsent
three weeks apart) with the corresponding authors of
100trialsrandomlyselectedamongthosenotreporting
SF-36data.Selectionwasbasedonalistof100numbers
generated randomly and applied to the 1057 retrieved
articles,orderedseriallyperjournal,afterexcludingthe
52 eligible articles.
Data extraction
Data were extracted by three independent investiga-
tors (IK, AK, and DGC-I). Discrepancies were
resolved by consensus. Remaining disagreements
were resolved by JPAI.
From each eligible article we extracted information
on authors, journal, design (superiority or non-
inferiority), condition, interventions compared, sam-
plesize (randomised,analysedforSF-36), definition of
primary efficacy outcome (as reported; if not clarified,
we selected the outcome used for sample size calcula-
tions), time points and statistical analysis for the
primary outcome and SF-36 assessments, whether
SF-36 was a co-primary outcome, and whether any
other quality of life and health related survey scales
were used. We also recorded which SF-36 scores were
reported and for which we could obtain missing
information from authors.
Discordant results
For the primary efficacy outcome and for each of the
presented SF-36 assessments we recorded whether the
difference between compared arms was statistically
significant (P<0.05) favouring the experimental arm,
non-statistically significant, or statistically significant
favouring the control arm. For trials with more than
two arms we considered the comparison of each
experimental intervention against control separately.
Weconsideredallcomparisonsandalsopresentresults
separately for superiority and non-inferiority trials.
15
Data on SF-36 outcomes were extracted for the
reported analyses that corresponded as closely as
possibletothesametimepointsasforprimaryoutcome
data. Specifically, when measurements for primary or
SF-36outcomeswerecarriedoutatseveraltimepoints,
for primary efficacy outcomes we preferred analyses
accounting for multiple measurements (for example,
repeatedmeasurementanalysis)thananalysesofsingle
timepoints.Iftheprimaryoutcomewasatimetoevent
analysis or incorporated serial longitudinal measure-
ments, we preferred the analysis of serial longitudinal
SF-36 measurements; if this was unavailable, we
recorded whether there was formal statistically sig-
nificant difference at any time points when SF-36 had
been appraised. When the primary outcome was
appraised at a single time point, we recorded the SF-
36 outcomes at the single same (or closest) time point.
In two comparisons where co-primary outcomes
existed and could not be prioritised, we based the
evaluationofstatisticalsignificanceonoverallauthors’
interpretation.
We considered SF-36 results as statistically signifi-
cant when at least one of the composite or subdomain
scores showed a statistically significant result in favour
or against the experimental intervention. There were
no situations where some of the specific SF-36 scores
were significant for the experimental intervention and
others were significant against.
For statistically significant SF-36 effects when the
respective primary efficacy outcome was discordant,
we extracted information on the effect size of SF-36.
Roughly, standardised mean differences of less than
0.30standarddeviationsaresmalleffects,0.30-0.80are
moderate, and more than 0.80 are large.
16-20 The
correspondingcut-offsforrawscoresarelessthan4,4-
10, and more than 10 points.
For comparisons with discordant statistical signifi-
cance on SF-36 and primary outcome results, we
recorded whether the authors had discussed the SF-36
results at all, whether they commented on the
discrepancy and if so with what arguments, and if SF-
36 findings changed the interpretation of the trial
results.
Excluded (n=993):
  No data on SF-36 or SF-12
Excluded (n=12):
  Not randomised controlled trial (n=2)
  No data on SF-36 or SF-12 (n=2)
  SF-36 or SF-12 mentioned only as reference (n=8)
Potentially relevant randomised controlled trials identified 
and screened electronically in full text (n=1057) 
Articles retrieved for more detailed evaluation (n=64) 
Randomised controlled trials with usable information (n=52) 
Flow chart of papers through trial
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Overall 1057 trials were screened and 52 eligible trials
identified
w1-w52with66eligiblecomparisons(figureand
web extra table). Additional data were presented in
other published articles on primary efficacy for one
trial
w43 and SF-36 for eight trials.
w4 w21 w24 w29 w35 w36 w46
w51AdditionalSF-36datawereprovideddirectlybythe
authorsin11trialswith13comparisons(seewebextra
fig 1). Forty two trials (56 comparisons) addressed
superiority, and 10 (10 comparisons) non-inferiority.
Inseventrials(10comparisons)
w2 w8 w35 w39 w40 w44w45SF-
36 wasdescribedasa co-primary outcome.Additional
qualityoflifeorhealthsurveyinstrumentsappearedin
16 trials (16 comparisons).
Eventually, data for physical composite score and
mental composite score were available for 34 trials (39
comparisons) and 35 trials (40 comparisons, see web
extrafig1).Dataonatleastoneoftheeightsubdomain
scores were available for 36 trials (48 comparisons).
Data on all possible SF-36 scores were available for 18
trials (eight published, 10 obtained from authors). Six
trials
w6 w23 w29 w31 w35 w44 had collected information a
priori only for specific subdomains.
Concordance of results
Of the 66 comparisons, 21 (32%) had discordant
statistical significance for primary efficacy and SF-36
results (table 1). Moreover, of the 56 comparisons of
superiority trials 19 had discordant primary efficacy
and SF-36 results (see web extra fig 2).
In one
w44 of the 21 discrepancies, SF-36 was a co-
primary outcome. In seven discrepancies, additional
quality of life or health survey instruments were also
used. In two trials
w14 w51 the additional instruments
agreed with SF-36, and in five
w12 w15 w31 w44 w47 they
agreed with the primary efficacy outcome.
In the 13 discordant comparisons with only SF-36
significantresults(ninecomparisonsinfavourandfour
againsttheexperimentalintervention;inseventrials
w7
w14 w21 w31 w44 w46 w47 and three trials,
w15 w43 w51 respec-
tively) there were 17 statistically significant specific
scores (five normalised, 10 raw, two reporting only
statistical significance without effect size); effect sizes
were small in six, moderate in six, and large in three.
Interpretation of trial findings in discordant settings
Improvedprimaryoutcomeonly—SF-36resultsdid
not modify the trial’s interpretation of these 11
comparisons (eight trials, table 2).
w4 w12 w16 w18 w41 w42
w43 w51Infivecomparisons(fourtrials),SF-36outcomes
wereonlytabulatedoralludedtointheresults,without
further discussion.
w12 w16 w18 w42 In the other four trials
theauthorsfocusedonothernon-primaryoutcomes,
w4
claimed that SF-36 was not sensitive enough to detect
improvements,
w41 adopted a non-intention to treat
analysis for SF-36 with significant results,
w43 or
dismissed the importance of the negative effects on
SF-36 in the face of benefits in disease-free survival.
w51
Improved SF-36 only—SF-36 modified the inter-
pretationofonlytwotrials.
w31 w44Theauthorsfavoured
the peer modelling videotape for breast cancer based
on the significant and large improvement on SF-36
vitality despite no improvement on the IES-R (revised
impact of events scale) (both were co-primary out-
comes,table 2).
w44Inthechronicrenalfailureanaemia
trial the benefit in vitality score from erythropoietin
was acknowledged as clinically important.
w31 In the
other five comparisons (three trials), benefits on SF-36
did not change the interpretation.
w7 w14 w21 One trial
dismissed the SF-36 difference as transient and
weak,
w14 one trial considered the non-statistically
significant benefits in efficacy as clinically important,
whereas the significant improvementsin SF-36 vitality
scores were considered clinically unimportant and the
authors then even questioned the use of SF-36 in trials
on diabetes,
w21 and in another trial the authors
considered that the clinical significance of statistically
significant differences in SF-36 domains in patients
with fibromyalgia could not be evaluated.
w7
Improved SF-36, non-inferiority on primary
outcome—SF-36 did not modify the interpretation of
these two trials.
w46 w47 Both trials already concluded
favourably for the experimental intervention that
achieved the desired non-inferiority, and in one of
them
w47 the observed benefit in SF-36 was considered
possibly due to chance.
OnlySF-36worsened—Inonetrial
w15whereSF-36
worsened with the experimental intervention, the
investigators interpreted the results as showing no
consistent differences in quality of life, because an
additional instrument (EQ5D) showed no significant
differences.
Probing unpublished data
Authors of 69 of 100 additional randomly selected
trials responded. SF-36 data had actually been col-
lected from five trials. The data had been analysed for
only one trial and did not show any statistically
significantdifferencesforSF-36ortheprimaryefficacy
outcome.
DISCUSSION
In one third of the trial comparisons in our empirical
evaluation, differential effects on primary efficacy
outcomes compared with SF-36 were identified.
However, when SF-36 compared with efficacy
Table 1 |Concordance of statistical significance in SF-36 and primary outcome results
Primary outcome
SF-36 results
Significant* Non-significant Significant (against)† Total
Significant 21 8 3 32
Non-significant 9‡ 23 1 33
Significant (against) 0 0 1 1
Total 30 31 5 66
κ coefficient 0.33 (95% confidence interval 0.06 to 0.59) for concordance of primary outcome against SF-36. No
situations occurred where specific SF-36 scores were significant for experimental intervention and others were
significant against.
*At least one of composite or subdomain scores shows statistically significant result in favour of experimental
intervention.
†At least one of composite or subdomain scores shows statistically significant result against experimental
intervention.
‡This category contains the only two studies (w31 and w44) where interpretation of study findings was modified
based on SF-36 results.
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Author (reference) Condition Comparison
Primary efficacy
outcome Interpretation
Improved primary
outcome only:
Campbell
w4* Refractory ascites Transjugularintrahepaticportal-
systemic shunt+large volume
paracentesis(asneeded)vlarge
volume paracentesis (as
needed)
Ascites recurrence Improvement in primary outcome considered not worth it because of no survival
benefit and possible worsening of encephalopathy; these competing effects
considered to nullify any changes in quality of life
Devière
w12 Gastroesophageal
reflux
Endoscopic implantation of
biocompatible non-resorbable
copolymer (Enteryx; Boston
Scientific) v sham procedure
Reductioninuseofproton
pump inhibitor
SF-36 outcomes only alluded to in results, without discussion
Fairbank
w16 Chronic low back
pain
Surgical treatment v intensive
rehabilitation
Oswestry disability index
score
SF-36 outcomes tabulated only in results, without discussion
Gilron
w18 Neuropathic pain Garbapentin+morphine v
morphine
Mean daily pain score SF-36 outcomes alluded to only in results, without discussion
Shaheen†w41 Ulceration after
band ligation
Pantoprazole v placebo Size of oesophageal ulcer SF-36 considered not sensitive enough to detect improvements
Sherman
w42 Chronic low back
pain
Yoga v self care book; yoga v
exercise
Roland-Morris disability
questionnaire score
SF-36 outcomes alluded to only in results, without discussion
Singh†‡
w43 Atrial fibrillation Amiodarone v sotalol;
amiodaronevplacebo;sotalolv
placebo
Recurrence of atrial
fibrillation
Amiodarone v sotalol, and amiodarone v placebo: briefly mentioned in results
that amiodarone associated with significantly worse mental health scores
(P=0.005,noeffectsizeprovided)andfocusedonnon-intentiontotreatanalysis
(patientsonsinusrhythmvwithrecurrentarrhythmia);sotalolvplacebo:focused
on non-intention to treat analysis (patients on sinus rhythm v with recurrent
arrhythmia)
Whelan*
w51 Breast cancer Letrozol v placebo Disease-free survival NegativeeffectsonSF-36dismissedinfaceofsignificantbenefitsindisease-free
survival; three subdomains affected, but SF-36 effects considered transient and
small (<0.2 SD)
Improved SF-36 only:
Stanton§¶w44 Breast cancer (re-
entry phase after
surgery)
Peer modelling videotape v
standard print material alone
Revised impact of events
scale score
Peermodellingvideotape was favoured basedonsignificantand large (0.92 SD)
improvementonSF-36vitalitydespitenoimprovementonIES-R;SF-36andIES-R
were co-primary outcomes
Parfrey¶w31 Anaemia in renal
failure
Erythropoietin for high v low
target haemoglobin
Left ventricular volume
index
Benefit in vitality score (0.35 SD) acknowledged as clinically important and as
“only consistent benefit conferred by normalizing hemoglobin in patients with
chronic kidney disease”
Crofford
w7 Fibromyalgia Pregabalin (150 mg) v placebo;
pregabalin (300 mg) v placebo
Pain score Pregabalin 150 mg and 300 mg offered moderate benefits in general health (4.6
and5.9points,respectively),eventhoughtheirclinicalsignificancewasdeemed
uncertain
EVAR 1
w14 Abdominal aortic
aneurysm
Endovascular v open repair of
aneurysm
All cause mortality Benefitinphysicalcomponentscoredismissedbecausedifferencewastransient
and not strong (0.17 SD)
Hill-Briggs*
w21 Type 2 diabetes Nurse case manager v usual
care;communityhealthworkerv
usual care
Haemoglobin A1C Nurse case manager v usual care: non-statistically significant decrease in
haemoglobin A1C levels was considered “clinically important” and significant
improvements of moderate magnitude (8.53 points) in SF-36 vitality scores
considered clinically unimportant; community health worker v usual care: as
above with improvement in vitality score of 6.34 points. SF-36 use in diabetes
trials was questioned
Improved SF-36, non-
inferiority on primary
outcome:
Sweeney*
w46 Fast ventricular
tachycardia
Antitachycardia pacing v shock
first (with implantable
cardioverter defibrillator)
Duration of fast
tachycardia
Experimental intervention was favoured because it “is highly effective, equally
safe and improves quality of life.” Effect sizes for significant SF-36 scores were
moderate or large (5, 12, 20 points)
UKATT
w47 Alcoholism Social behaviour and network
therapy v motivational
enhancement
Days of abstinence Experimental intervention worth adopting based on primary efficacy results.
Observedbenefitinphysicalcompositescorewassmall(0.13SD)andconsidered
as possibly “due to chance”
OnlySF-36worsened:
EVAR 2
w15 Abdominal aortic
aneurysm (unfit for
repair)
Endovascular repair of
aneurysm v no repair
All cause mortality Authors already concluded against experimental intervention because of no
survivalbenefitandneedforcontinuoussurveillanceandreintervention.Authors
saw no clear and consistent differences in quality of life. EQ5D quality of life
showed no significant differences and SF-36 detrimental effect was small (0.19
SD)
EQ5D=EuroQoL-5 dimension; IES-R=revised impact of events scale score. Only discordant comparisons per trial are shown; additional comparisons may exist in same trial.
*Retrieved trial was separate publication for quality of life results. Corresponding publications with primary efficacy trial results: for Campbell
w4was Sanyal et al. Gastroenterology
2003;124:634-41; for Hill-Briggs
w21 was Garry et al. Prev Med 2003;37:23-32; for Sweeney
w46 was Wathen et al. Circulation 2004;110:2591-6; and for Whelan
w51 was Goss et al. NE n gJM e d
2003;349:1793-802.
‡Retrieved trial was separate publication for primary efficacy outcomes only. Corresponding publication with SF-36 results for Singh
w43 was Singh et al. JA mC o l lC a r d i o l2006;48:721-30.
§SF-36 questionnaire was a co-primary outcome for Stanton
w44 among two primary outcomes.
¶Overall interpretation of study was modified by SF-36 results.
†Authors had provided additional SF-36 data after contact.
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rarely affected the interpretation of these trials. What
weobservedwasgenerallyatendencytobelittlerather
thantopronouncediscordantresults.Severaltrialsdid
not discuss the SF-36 findings at all, and most did not
reportallthetestedSF-36scores.Consideringposthoc
an instrument as insensitive or not worth reporting
contradicts the initial choice to use this instrument as a
trial outcome.
In most trials for chronic conditions, quality of life
and surveys of health status are useful to consider. SF-
36 was reported in fewer than 5% of the trials we
screened, and our author survey suggested that some
additional trials (at least five of 100) had collected
informationonSF-36butwithoutanalysingorpublish-
ingittwoorthreeyearsafterthepublicationofthemain
trial results. Quality of life seems to remain under-
valued in clinical research: few trials collect quality of
life related data, fewer report on them, data are only
partiallypresented, and quality of liferarely affects the
trial interpretation.
We should acknowledge some caveats. Firstly, by
selecting high impact journals we identified trials with
high visibility and probably also high quality.
21 It is
unlikely that this strategy would have selected for
discordant results between outcomes. Secondly, selec-
tive analysis and reporting bias may affect primary
outcomes and not just SF-36,
22-25 but this should not
have increased the perceived rate of discrepancies
betweenoutcomes.Thirdly,discordanceatthelevelof
statistical significance does not necessarily mean that
results for different outcomes differ beyond chance.
Among statistically significant results, chance findings
and non-clinically important differences are possible,
andprimaryoutcomesshouldbegivenmoreweightin
the discussion than secondary outcomes. Given that
trials are typically powered to address the primary
outcome, a significant result in the primary outcome
with a non-significant result in quality of life or health
survey assessments may sometimes simply reflect lack
of power for the quality of life or health survey
outcome.Thereforewe alsoexaminedtheSF-36effect
sizes and the circumstances and discussion of discor-
dantresults.Fourthly,wedidnotcarryoutthesamein-
depth evaluation for trials where efficacy and SF-36
outcomes were concordant. It is unlikely that authors
would then have modified their inferences, but SF-36
mayhavestrengthenedtheconclusions.Finally,wedid
not examine trials using only other quality of life or
health survey instruments beyond SF-36. However,
SF-36 is the most robustly standardised and widely
used one, and we wanted to maximise comparability.
Although other scales may also be used, one study
foundthatonly4.2%oftrialsreportedanyqualityoflife
outcome.
2
Althoughqualityoflifeandhealthsurveyscaleshave
been used in clinical trials for over 25 years, several
issuesremaindebated.
26Besidesproblemsoffragmen-
ted, selectively reported information, it is sometimes
impossible to say whether and which analyses are
based on a priori analytical plans.
1127 Proper attention
totheimportanceoftheseoutcomesshouldbegivenin
clinical trials. Otherwise, with a growth in the clinical
trials’ administrative paperwork,
28 outcomes such as
SF-36 may become routine compulsory assessments
without a genuine interest to learn from them.
Overall,qualityoflifeandhealthsurveyassessments
provide a different window into patient outcomes and
deserve to be included in more trials with complete
reporting of results, and standardised interpretation.
Unbiased data on these outcomes may enhance our
ability to improve clinical decision making.
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